MaxCyte Q1 2023 Earnings Report

MaxCyte EPS Results

• Actual EPS: -$0.11
• Consensus EPS: -$0.11
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

MaxCyte Revenue Results

• Actual Revenue: $8.58 million
• Expected Revenue: $8.75 million
• Beat/Miss: Missed by -$170.00 thousand
• YoY Revenue Growth: N/A

MaxCyte Announcement Details

• Quarter: Q1 2023
• Date: 5/10/2023
• Time: N/A

MaxCyte (NASDAQ:MXCT), a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.